NVO · NYSE · STOCK
Novo Nordisk A/S (NVO) Stock Analysis
$38.62
52W $35.12 – $64.16
53/100
$171.59B
9.7
0.35
Is NVO Bullish or Bearish?
Mixed.
Innellis AI committee rates Novo Nordisk A/S (NVO) Watch with a composite score of 53/100
, based on 6 analysts with 50% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +6.76 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -13.24 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- P/E of 9.5 is inexpensive for the broad market — Value
- ROE of 59.1% shows genuine earnings power backing the valuation — Value
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (downtrend) confirms the daily trend -- multi-timeframe agreement — Technical
- News sentiment is positive (+0.20 across 112 articles, 14d) — News
Bear Case
- Price-to-book of 7.4x prices in significant intangible value — Value
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- Price structure making lower highs and lower lows — Technical
- Current ratio of 0.80 is tight -- limited short-term liquidity cushion — Risk
- Bollinger bandwidth of 21.6% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
53/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 77%
of 192 Healthcare peers
Value Analyst
bullish
62
/ 100 · Moderate confidence
Classic value case: cheap on multiples with earnings power to back it up
+ P/E of 9.5 is inexpensive for the broad market
− Price-to-book of 7.4x prices in significant intangible value
Growth Analyst
bearish
38
/ 100 · Moderate confidence
Growth story is weak, decelerating, or inconsistent
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst
neutral
56
/ 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
− Price structure making lower highs and lower lows
Risk Analyst
bearish
35
/ 100 · Moderate confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Current ratio of 0.80 is tight -- limited short-term liquidity cushion
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
64
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.20 across 112 articles, 14d)
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 53.4 to 53.2.
- New bearish signals: 1 appeared.
- Bullish support removed: 2 signal(s) disappeared.
- New bullish signals: 2 appeared.
- Bearish pressure eased: 1 signal(s) disappeared.
Analyst-level changes:
- News Analyst: +1 bullish signal(s).
- Risk Analyst: +1 bearish signal(s).
- Value Analyst: +1 bullish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
46.4
Neutral
MACD Histogram
0.188
Bullish Momentum
Trend Direction
Downtrend
Weekly: Downtrend
Market Structure
Mixed
Support
$35.13
Resistance
$47.75
Bollinger %B
0.40
Inside Bands
Price vs Moving Averages
EMA 9
$38.30
Above
EMA 21
$39.74
Below
EMA 50
$42.35
Below
EMA 200
$47.05
Below
Fundamental Analysis
Valuation
66
Growth
26
Profitability
100
Financial Health
50
Cash Flow
70
Valuation
P/E Ratio
9.7×
P/B Ratio
5.11×
PEG Ratio
1.94
Dividend Yield
4.58%
52W High
$64.16
52W Low
$35.12
Quality & Growth
ROE
5278.8%
ROA
1886.8%
Gross Margin
8064.8%
Operating Margin
4313.4%
Revenue Growth YoY
—
Debt / Equity
0.63
AI Fundamental Assessment
P/E ratio of 9.7 (inexpensive relative to a 15-40x range); Price-to-book of 5.1x; PEG ratio of 1.9 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 52.8%; Return on assets of 18.9%; Net margin of 35.3%; Gross margin of 80.6%; Current ratio of 0.87 (tight short-term liquidity); Debt-to-equity of 0.63; Free cash flow per share is positive (11.05); Most recent quarter missed estimates by 5.6%; EPS growth decelerating (+9.8% -> -28.4% QoQ); Average YoY EPS growth of -20.3%; Analyst estimates falling over recent quarters
Get the Full NVO Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →